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The “one size fits all” concept is rarely applicable in life, this is also true for the concept of continuous 
manufacturing where specific applications will differ based upon the requirements of the end user.   This is the 
scenario we describe here in which aspects of continuous manufacturing for both upstream and downstream 
biologics manufacturing are being incorporated to address the current pipeline needs within Bristol-Myers 
Squibb.  The application is for stable, easily expressed monoclonal antibody processes that require moderate 
volumes and throughputs, such as for most oncology or immuno-oncology therapies.  However, this is 
countered by challenges of an expanding pipeline that necessitates looking beyond the current platform 
philosophy for how to modify the process with the goal to increase overall productivity in a flexible manner.   
 
BMS recently constructed a clinical biologics manufacturing facility on the Devens, Massachusetts campus with 
operations being initiated in two phases.  The first phase start-up aligned with a traditional, but flexible (i.e., 
based upon disposable technologies) upstream and downstream processes and was rapidly brought on 
line.  The second phase is the design and construction within that same manufacturing building purposely left 
unfinished to allow for the process development group to design and demonstrate a next generation concept for 
manufacturing.  With respect to the upstream process, the decision was made to maintain a fed-batch 
production bioreactor philosophy, but to employ much higher inoculation densities through use of perfusion 
culture at the seed bioreactor stage generating the inoculum.  This results in cultures with shorter durations and 
opportunities for increased titer.  Selection of the overall cycle time is an optimization between cadence and 
bioreactor throughput.  With respect to the downstream processes, numerous continuous manufacturing 
technologies were evaluated to handle the increased titers being generated in the bioreactors.  These 
downstream technologies include continuous harvest technologies, multicolumn continuous chromatography for 
capture, integrated pool-less polishing steps, automated viral inactivation, single pass TFF and in-line 
diafiltration.  The advantages for manufacturing cadence and overall throughput, as well as other outcomes 
including efforts to decrease perfusion media usage, and a significant reduction in downstream resin costs will 
be presented.  Once the second phase is implemented, the facility will accommodate both traditional as well as 
this hybrid model for continuous manufacturing interchangeably.  The overall benefit to support multiple clinical 
products and the higher titer/throughputs are expected to reduce the number of batches as well as eliminate 
resupply batches for clinical supply. 
 
